Compression Therapy for HIV-Associated Kaposi Sarcoma Leg Lymphedema: Results of the Kenyan Improvised Compression for Kaposi Sarcoma Randomized Controlled Trial

dc.contributor.authorChang, Aileen Y.
dc.contributor.authorKarwa, Rakhi
dc.contributor.authorOdhiambo, Haji
dc.contributor.authorWere, Phelix
dc.contributor.authorFletcher, Sara L.
dc.contributor.authorTonui, Edith C.
dc.contributor.authorKohn, Michael A.
dc.contributor.authorLee, Jeannette
dc.contributor.authorChang, Di
dc.contributor.authorLensing, Shelly
dc.contributor.authorNamaemba, Diana Flora
dc.contributor.authorBusakhala, Naftali
dc.contributor.authorKiprono, Samson K.
dc.contributor.authorMaurer, Toby
dc.contributor.authorGoodrich, Suzanne
dc.contributor.authorPastakia, Sonak D.
dc.contributor.departmentDermatology, School of Medicineen_US
dc.date.accessioned2023-04-26T12:53:43Z
dc.date.available2023-04-26T12:53:43Z
dc.date.issued2022
dc.description.abstractPurpose: Evaluate the effectiveness of compression while receiving chemotherapy compared with chemotherapy alone in the treatment of HIV-associated Kaposi sarcoma (KS) lymphedema. Methods: A randomized controlled trial was conducted in a single oncology clinic in western Kenya (NCT03404297). A computer-generated randomization schedule was used to allocate treatment arms. Randomized block design was used for stratification by lymphedema stage. Participants were HIV positive adults age ≥ 18 years on antiretroviral therapy with biopsy-proven KS associated with leg lymphedema and being initiated on chemotherapy. The intervention was 10 weeks of weekly clinic-based application of two-component paste compression bandages. The primary outcome was change in the Lower Extremity Lymphedema Index (LELI) score from week 0 to week 14. The secondary outcomes were change in the Lymphedema Quality of Life measure (LYMQOL) and change in the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 score from week 0 to week 14. Blinded outcome assessments were conducted. Results: Of 30 participants randomly assigned, 25 eligible patients (chemotherapy [control], n = 13; compression plus chemotherapy [intervention], n = 12) returned at week 14. Change in LELI, LYMQOL, and EORTC QLQ-C30 scores between week 14 and week 0 did not significantly differ by arm. The mean (standard deviation) change in LELI score was -25.9 (34.6) for the control arm compared with -13.3 (29.5) for the intervention arm, P = .340. The difference (95% CI) in the change in LELI score was -12.6 (-39.3 to 14.1). Conclusion: Future studies evaluating a 14-week change in LELI for KS lymphedema should assume a standard deviation of approximately 30. Lessons learned from this pilot trial should inform the development of a larger, multicenter trial to evaluate the effectiveness of compression for KS lymphedema.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationChang AY, Karwa R, Odhiambo H, et al. Compression Therapy for HIV-Associated Kaposi Sarcoma Leg Lymphedema: Results of the Kenyan Improvised Compression for Kaposi Sarcoma Randomized Controlled Trial. JCO Glob Oncol. 2022;8:e2100329. doi:10.1200/GO.21.00329en_US
dc.identifier.urihttps://hdl.handle.net/1805/32600
dc.language.isoen_USen_US
dc.publisherAmerican Society of Clinical Oncologyen_US
dc.relation.isversionof10.1200/GO.21.00329en_US
dc.relation.journalJCO Global Oncologyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePMCen_US
dc.subjectHIV infectionsen_US
dc.subjectLymphedemaen_US
dc.subjectKaposi sarcomaen_US
dc.titleCompression Therapy for HIV-Associated Kaposi Sarcoma Leg Lymphedema: Results of the Kenyan Improvised Compression for Kaposi Sarcoma Randomized Controlled Trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
go-8-e2100329.pdf
Size:
558.88 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: